Eight Cycles of Escalated-Dose BEACOPP Compared With Four Cycles of Escalated-Dose BEACOPP Followed by Four Cycles of Baseline-Dose BEACOPP With or Without Radiotherapy in Patients With Advanced-Stage Hodgkin's Lymphoma: Final Analysis of the HD12 Trial of the German Hodgkin Study GroupPeter Borchmann, Andreas Engert, Heinz Haverkamp et al.|Journal of Clinical Oncology|2011Cited by 190
Suppressed neutrophil function as a risk factor for severe infection after cytotoxic chemotherapy in patients with acute nonlymphocytic leukemiaKai Hübel, Andreas Engert, K. Hegener et al.|Annals of Hematology|1999Cited by 55
Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin’s lymphomaPeter Borchmann, Andreas Engert, R Knippertz et al.|Annals of Oncology|2001Cited by 52
A Catalyst for Change: The European Cancer Patient's Bill of RightsMark Lawler, Patrick G. Johnston, Thierry Le Chevalier et al.|The Oncologist|2014Cited by 46